Shandong Weigao Blood Purification Products Co., Ltd. Class A

Shandong Weigao Blood Purification Products Co., Ltd. Class A

SSSE:603014
34.98
CNY
-0.09
(-0.26%)
2.06EPS
14.95P/E
21.39BMarket Cap
Mar 29Next Earn

Total Valuation

CNY

As of September 30, 2026, Shandong Weigao Blood Purification Products Co., Ltd. Class A carries a market capitalization of 21.39B, placing it among publicly traded companies globally. Its enterprise value stands at 17.86B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap21.39B
Enterprise Value17.86B

Important Dates

Shandong Weigao Blood Purification Products Co., Ltd. Class A's next confirmed earnings release is scheduled for March 29, 2027.

Earnings Date3/29/2027

Share Statistics

As of September 30, 2026, Shandong Weigao Blood Purification Products Co., Ltd. Class A has 694.80M shares outstanding.

Shares Outstanding694.80M

Valuation Ratios

As of September 30, 2026, Shandong Weigao Blood Purification Products Co., Ltd. Class A trades at a trailing price-to-earnings ratio of 14.95. The price-to-sales ratio is 2.78, and the price-to-book ratio stands at 1.97.

PE Ratio14.95
PS Ratio2.78
PB Ratio1.97
P/TBV Ratio2.03

Enterprise Valuation

As of September 30, 2026, Shandong Weigao Blood Purification Products Co., Ltd. Class A trades at an EV/EBITDA multiple of 15.11 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 3.31 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 15.11 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 17.86B versus a market cap of 21.39B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales3.31
EV / EBITDA15.11
EV / EBIT15.11

Financial Position

As of September 30, 2026, Shandong Weigao Blood Purification Products Co., Ltd. Class A maintains a current ratio of 3.94, meaning it holds 3.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.67, indicating elevated leverage, while an interest coverage ratio of 227.01 demonstrates strong ability to service its debt obligations.

Current Ratio3.94
Quick Ratio2.15
Debt / Equity1.67
Debt / EBITDA0.15
Interest Coverage227.01

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Shandong Weigao Blood Purification Products Co., Ltd. Class A posted a return on equity (ROE) of 11.38, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 11.25 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.61, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 11.31, useful for judging operating efficiency across full business cycles. The company generates approximately 1.45M in revenue per employee across its workforce of 3,734.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.94 indicates how many times Shandong Weigao Blood Purification Products Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)11.38
Return on Assets (ROA)9.61
Return on Invested Capital (ROIC)11.25
Return on Capital Employed (ROCE)11.31
Revenue Per Employee1.45M
Employee Count3,734.00
Inventory Turnover2.94

Taxes

CNY

Over the twelve months ended September 30, 2026, Shandong Weigao Blood Purification Products Co., Ltd. Class A recorded 170.12M in income tax expense. That works out to an effective tax rate of 14.48, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.18B, leaving 1.01B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax170.12M
Effective Tax Rate14.48

Stock Price Statistics

CNY

As of the close on November 17, 2026, Shandong Weigao Blood Purification Products Co., Ltd. Class A's stock has declined approximately 15.77% over the past 52 weeks. The 50-day moving average sits at 31.35, while the 200-day moving average is 34.83.

52-Week Price Change-15.77%
50-Day Moving Average31.35
200-Day Moving Average34.83

Income Statement

CNY

Over the twelve months ended September 30, 2026, Shandong Weigao Blood Purification Products Co., Ltd. Class A generated 5.40B in revenue and converted that into 1.01B in net income, yielding earnings per share of 2.06. EBITDA reached 1.18B, while operating income came in at 1.14B.

Revenue5.40B
Gross Profit2.21B
Operating Income1.14B
Pretax Income1.18B
Net Income1.01B
EBITDA1.18B
EBIT1.18B
Earnings Per Share (EPS)2.06

Balance Sheet

CNY

As of September 30, 2026, Shandong Weigao Blood Purification Products Co., Ltd. Class A holds 3.71B in cash and equivalents against 181.24M in total debt, resulting in a net debt position of -1.77B. Total book value stands at 10.88B, with working capital of 5.06B providing operational flexibility.

Cash & Cash Equivalents3.71B
Total Debt181.24M
Net Debt-1.77B
Equity (Book Value)10.88B
Book Value Per Share15.65
Working Capital5.06B

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-200.15M

Margins

Over the twelve months ended September 30, 2026, Shandong Weigao Blood Purification Products Co., Ltd. Class A posted a gross margin of 40.99, reflecting its pricing power and cost economics. The operating margin of 21.06 and net profit margin of 18.62 provide insight into operational efficiency.

Gross Margin40.99
Operating Margin21.06
Pretax Margin21.76
Profit Margin18.62
EBITDA Margin21.89

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Shandong Weigao Blood Purification Products Co., Ltd. Class A paid dividends of 0.18 per share. The dividend payout ratio of 8.76 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Dividend Per Share0.18
Payout Ratio8.76

Scores

As of September 30, 2026, Shandong Weigao Blood Purification Products Co., Ltd. Class A has an Altman Z-Score of 8.44, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score8.44